NASDAQ:ADMA ADMA Biologics (ADMA) Stock Price, News & Analysis $11.46 +0.25 (+2.23%) (As of 07/5/2024 08:52 PM ET) Add Compare Share Share Today's Range$11.01▼$11.4750-Day Range$6.52▼$11.5552-Week Range$3.06▼$11.68Volume2.03 million shsAverage Volume2.83 million shsMarket Capitalization$2.66 billionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get ADMA Biologics alerts: Email Address ADMA Biologics MarketRank™ Stock AnalysisAnalyst RatingBuy3.25 Rating ScoreUpside/Downside4.0% Downside$11.00 Price TargetShort InterestHealthy4.07% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$1.07 M Sold Last QuarterProj. Earnings Growth48.57%From $0.35 to $0.52 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.75 out of 5 starsMedical Sector771st out of 879 stocksBiological Products, Except Diagnostic Industry135th out of 150 stocks 1.6 Analyst's Opinion Consensus RatingADMA Biologics has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageADMA Biologics has only been the subject of 4 research reports in the past 90 days.Read more about ADMA Biologics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.07% of the outstanding shares of ADMA Biologics have been sold short.Short Interest Ratio / Days to CoverADMA Biologics has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ADMA Biologics has recently increased by 2.50%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldADMA Biologics does not currently pay a dividend.Dividend GrowthADMA Biologics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ADMA. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for ADMA Biologics this week, compared to 3 articles on an average week.Search InterestOnly 36 people have searched for ADMA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 12 people have added ADMA Biologics to their MarketBeat watchlist in the last 30 days. This is a decrease of -56% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ADMA Biologics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,072,000.00 in company stock.Percentage Held by InsidersOnly 3.70% of the stock of ADMA Biologics is held by insiders.Percentage Held by Institutions75.68% of the stock of ADMA Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ADMA Biologics' insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for ADMA Biologics are expected to grow by 48.57% in the coming year, from $0.35 to $0.52 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ADMA Biologics is -573.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ADMA Biologics is -573.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioADMA Biologics has a P/B Ratio of 19.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ADMA Biologics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 Media[Urgent] Hedge Funds Expect Major Crypto MovesIn the year following Bitcoin’s last Halving event, that happened in May of 2020… Bitcoin shot up over 550%. But that’s not all… Click here to register now. About ADMA Biologics Stock (NASDAQ:ADMA)ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Read More ADMA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADMA Stock News HeadlinesJune 15, 2024 | insidertrades.comADMA Biologics, Inc. (NASDAQ:ADMA) CEO Adam S. Grossman Sells 100,000 SharesJuly 3, 2024 | americanbankingnews.comADMA Biologics (NASDAQ:ADMA) Sets New 52-Week High at $11.28July 8, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on August 19.May 12, 2024 | seekingalpha.comGiving ADMA Biologics A Well-Deserved 'Booyah'May 11, 2024 | cnn.comADMA Biologics, Inc.May 11, 2024 | finance.yahoo.comADMA Biologics First Quarter 2024 Earnings: Beats ExpectationsMay 10, 2024 | markets.businessinsider.comStrong Financial Performance and Growth Prospects Affirm Buy Rating for ADMA BiologicsMay 10, 2024 | marketwatch.comADMA Biologics Shares Rise 23% After 1Q Earnings Beat EstimatesJuly 8, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on August 19.May 10, 2024 | msn.comADMA Biologics hits 52-week high on Q1 beat, guidance raiseMay 10, 2024 | finance.yahoo.comADMA Biologics Inc (ADMA) Surpasses Analyst Revenue and Earnings Forecasts in Q1 2024May 10, 2024 | finance.yahoo.comADMA Biologics, Inc. (NASDAQ:ADMA) Q1 2024 Earnings Call TranscriptMay 10, 2024 | msn.comADMA Biologics Analysts Increase Their Forecasts After Upbeat ResultsMay 9, 2024 | chron.comAdma Biologics: Q1 Earnings SnapshotMay 9, 2024 | markets.businessinsider.comADMA Stock Earnings: ADMA Biologics Beats EPS, Beats Revenue for Q1 2024May 9, 2024 | globenewswire.comADMA Biologics Announces First Quarter 2024 Financial Results and Provides Business UpdateMay 8, 2024 | markets.businessinsider.comADMA Biologics is about to announce its earnings — here's what to expectMay 6, 2024 | msn.comChart of the Day: ADMA Biologics - Hitting New HighsSee More Headlines Receive ADMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ADMA Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/07/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ADMA CUSIPN/A CIK1368514 Webwww.admabiologics.com Phone(201) 478-5552Fax201-478-5553Employees624Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$14.00 Low Stock Price Target$10.00 Potential Upside/Downside-4.0%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.02) Trailing P/E RatioN/A Forward P/E Ratio32.74 P/E GrowthN/ANet Income$-28,240,000.00 Net Margins-1.29% Pretax Margin-1.08% Return on Equity17.24% Return on Assets7.38% Debt Debt-to-Equity Ratio0.91 Current Ratio5.21 Quick Ratio1.86 Sales & Book Value Annual Sales$258.21 million Price / Sales10.29 Cash Flow$0.05 per share Price / Cash Flow225.51 Book Value$0.60 per share Price / Book19.10Miscellaneous Outstanding Shares231,810,000Free Float223,232,000Market Cap$2.66 billion OptionableOptionable Beta0.55 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Adam S. Grossman (Age 47)Co-Founder, President, CEO, Interim CFO & Director Comp: $1.59MDr. Jerrold B. Grossman D.P.S. (Age 76)Ph.D., Co-Founder & Vice Chairman of the Board Comp: $90kMs. Kaitlin Kestenberg (Age 37)COO & Senior VP of Compliance Mr. Drew PantelloVice President of Marketing & Corporate DevelopmentMs. Cindy PetersenExecutive Director of Human ResourcesMr. Skyler BloomSenior Director of Business Development & Corporate StrategyMr. Brad TadeVice President of Financial OperationsMore ExecutivesKey CompetitorsSolid BiosciencesNASDAQ:SLDBLogicBio TherapeuticsNASDAQ:LOGCChampions OncologyNASDAQ:CSBRQiagenNYSE:QGENVaxcyteNASDAQ:PCVXView All CompetitorsInsiders & InstitutionsFirst Hawaiian BankSold 32,315 shares on 7/2/2024Ownership: 0.039%Adam S GrossmanSold 100,000 sharesTotal: $1.07 M ($10.72/share)Castleark Management LLCBought 818,110 shares on 5/17/2024Ownership: 0.358%AWM Investment Company Inc.Sold 284,990 shares on 5/16/2024Ownership: 2.504%Kennedy Capital Management LLCSold 288,411 shares on 5/16/2024Ownership: 0.108%View All Insider TransactionsView All Institutional Transactions ADMA Stock Analysis - Frequently Asked Questions How have ADMA shares performed this year? ADMA Biologics' stock was trading at $4.52 at the beginning of 2024. Since then, ADMA shares have increased by 153.5% and is now trading at $11.46. View the best growth stocks for 2024 here. How were ADMA Biologics' earnings last quarter? ADMA Biologics, Inc. (NASDAQ:ADMA) posted its quarterly earnings results on Thursday, May, 9th. The biotechnology company reported $0.08 EPS for the quarter, beating the consensus estimate of $0.05 by $0.03. The company's revenue for the quarter was up 43.9% on a year-over-year basis. What is Adam S. Grossman's approval rating as ADMA Biologics' CEO? 9 employees have rated ADMA Biologics Chief Executive Officer Adam S. Grossman on Glassdoor.com. Adam S. Grossman has an approval rating of 29% among the company's employees. This puts Adam S. Grossman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are ADMA Biologics' major shareholders? ADMA Biologics' top institutional investors include First Hawaiian Bank (0.04%). Insiders that own company stock include Steve Elms, Adam S Grossman, Brian Lenz, Jerrold B Grossman, Young Kwon, Bryant Fong and Perceptive Advisors Llc. View institutional ownership trends. How do I buy shares of ADMA Biologics? Shares of ADMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of ADMA Biologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that ADMA Biologics investors own include Matinas BioPharma (MTNB), Pennsylvania Real Estate Investment Trust (PEI), Organigram (OGI), Tilly's (TLYS), Bionano Genomics (BNGO) and Novan (NOVN). This page (NASDAQ:ADMA) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredI’m giving you the name of this investment for freeThis key unlocks a new pathway to wealth that has been kept hidden from you for decades. In my new documen...Porter & Company | SponsoredOperation Replace Biden is a GoLast night’s debate proved me right: Joe Biden will be replaced. I’ve been making this warning for months… ...The Freeport Society | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADMA Biologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ADMA Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADMA Stock Alerts